TY -的T1 -口服皮质类固醇处方模式哮喘在法国,德国,意大利和英国摩根富林明-欧洲呼吸杂志》乔和J - 10.1183/13993003.02363 -2019欧元SP - 1902363 AU - Tran Trung联合国非盟-王,伊丽莎白盟——Sarkar Rajiv AU - Nan,卡桑德拉盟——罗宾侬安娜莉莎非盟-奥利里,卡罗琳盟——Muzwidzwa Ruvimbo AU -贝尔顿,劳拉盟——五胞胎,詹妮弗·k·Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/03/04/13993003.02363 - 2019. -抽象N2 -口服皮质类固醇(OCS)用于管理哮喘急性加重和严重,不受控制的哮喘,但口服避孕药使用与不良反应相关。我们的目的是描述在西欧哮喘患者的现实管理中使用OCS的模式。我们使用了2011年7月至2018年2月期间来自法国、德国、意大利和英国数据库的电子医疗记录。年龄≥12岁且诊断为哮喘的患者，诊断后±6个月内≥1次非ocs哮喘药物，以及队列进入前≥6个月和队列进入后≥90天的可用数据均被纳入。在随访期间，高剂量OCS的使用被定义为≥450 mg的OCS在90天的窗口期。随访期间的基线特征和OCS使用情况通过OCS使用状态进行总体描述。在702 685名哮喘患者中，14-44%的患者使用OCS, 6-9%的患者在随访期间的某个时间点使用OCS。在所有国家中，OCS高使用率的年流行率约为3%。高剂量的OCS服用者平均每年有1-3次OCS处方，每日平均OCS剂量为1.3-2.2 mg。 For patients who continued to meet the high use definition, daily OCS exposure was generally stable at 5.5–7.5 mg for at least 2 years, increasing the risk of adverse effects.Our study demonstrates that OCS use is relatively common across the four studied European countries. Data from this study may provide decisive clinical insights to inform primary care physicians and specialists involved in the management of severe, uncontrolled asthma.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Tran reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. King reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Sarkar reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Nan reports personal fees from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work.Conflict of interest: Dr. Rubino reports personal fees from Evidera, outside the submitted work.Conflict of interest: Dr. O'Leary reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Muzwidzwa reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Belton reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Quint reports other from Imperial College London, outside the submitted work. ER -